Skip to content
lifestyle.successxl.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Tenvie Therapeutics, Inc.
Tenvie Therapeutics Announces First Subject Dosed in Phase 1 Trial of TNV313, Expanding Its Fully CNS-Penetrant NLRP3 Franchise
October 13, 2026
Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV108, an Allosteric SARM1 inhibitor
April 20, 2026